#ExpertAnswers: Jay W. Mason & Mike Gralinski on ECG Interval and Arrhythmia Assessment
Airdate: Thursday, March 8, 2018 Season: 5 Episode: 3
Guests: Jay W. Mason, Michael Gralinski
In this episode of Expert Answers, Dr. Jay W. Mason and Mike Gralinski review advances in ECG safety assessment including reductions in interval measurement variability, reductions in confidence limits in concentration effect models and accurate reporting of up to 20 common arrhythmias.
For more information, to watch the webinar, or to download a copy of the full Q&A Report, click here.
Associated Webinar: Improving Preclinical and Clinical Regulatory Submissions Through Enhanced ECG Interval and Arrhythmia Assessment
Similar Podcasts
#ExpertAnswers: Artur Federowoski on Cardiovascular Dysautonomia in Post-COVID-19
Artur Federowski explains CV dysautonomia as a specific sequalae of acute COVID-19 and guides the audience in the diagnostic work-up of PASC patients with suspected cardiovascular complications.
#ExpertAnswers: Phil Griffiths on Telemetry Studies
Phil Griffiths draws from his experience as a telemetry user to discuss some important considerations for designing telemetry studies.
#ExpertAnswers: Cole McLarty, Nick Glover, and Tim Hacker on Pressure-Volume Loops
Cole McLarty, Nick Glover and Dr. Timothy Hacker focus on Pressure-Volume Loop collection and data analysis for cardiovascular research.
Related Content
Peripheral and Cerebral Vascular Responses Following High-Intensity Interval Exercise
Dr. Bert Bond and Max Weston will present an overview on their study investigating the effects high-intensity interval exercise has on cerebrovascular health.
Cardiovascular Autonomic Dysfunction in the Post-COVID Landscape: Detection and Management
Artur Fedorowski, MD, PhD, describes cardiovascular dysautonomia in COVID-19 and the diagnostics behind detecting Long COVID or Post-acute Sequalae of COVID-19.
APS Physiology in Disease Modeling and Drug Development Roundtable
Key opinion leaders in cardiovascular physiology and bioengineering discuss best practices and challenges when modeling cardiomyopathies and other cardiovascular diseases using stem cells, engineered tissues and other novel platforms.